相关实验视频

Updated: May 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

转移性前列腺癌向治疗的进展

Kabir Grewal¹, Tanya B Dorff², Sagar S Mukhida³

¹Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.

Current treatment options in oncology

|April 29, 2025

概括

生物标志物驱动的治疗正在彻底改变先进的前列腺癌护理. 聚ADP-ribose-polymerase (PARP) 抑制剂和雄激素受体 (AR) 途径抑制剂提供了新的希望,特别是对于具有特定突变的患者.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

先进的前列腺癌治疗正在从统一的方法发展到个性化,生物标志物引导的疗法.
进步的关键领域包括多ADP-ribose-polymerase (PARP) 抑制剂,新型雄激素受体 (AR) 向策略和细胞表面蛋白导向疗法.

研究的目的:

对转移性前列腺癌的现有和新兴治疗策略进行审查.
要突出PARP抑制剂,AR途径抑制剂和细胞表面蛋白向剂的作用.

主要方法:

审查当前文学和临床试验数据关于晚期前列腺癌的治疗方法.
具体治疗类别的讨论:PARP抑制剂,AR途径抑制剂,放射性联体疗法,双特异性T细胞参与剂和抗体-药物结合物.

主要成果:

用PARP抑制剂 (PARPi) 和AR途径抑制剂 (ARPI) 进行组合治疗,有利于同源复合修复 (HRR) 突变的转移性割抵抗性前列腺癌 (CRPC) 患者能够容忍它.
单独治疗PARPi可以使BRCA1或BRCA2突变不能耐受组合治疗的患者受益.
新的AR导向疗法 (配体降解剂,CYP11A1抑制剂) 对转移性CRPC有前途,可能有利于早期疾病阶段.
放射性干疗法 (Lu-PSMA-617) 是有效的PSMA-avid转移性CRPC后ARPI和化疗.
双特异性T细胞参与剂和针对细胞表面蛋白的新型放射性对象疗法显示出有希望的生存益处.

结论:

个性化医学,利用基于生物标志物的疗法,正在改变晚期前列腺癌的治疗.
PARP 抑制剂和 AR 导向疗法代表了显著的进步,组合策略和单一疗法提供了量身定制的选择.
通过放射性体疗法和双特异性T细胞参与剂向细胞表面蛋白质,为改善患者存活率提供了一个有希望的前沿.

关键词:

这就是为什么AR AR AR AR.细胞表面蛋白质是细胞表面蛋白质.修复DNA损伤的修复这是一种PARP抑制剂.这就是PROTAC.在PSMA上,PSMA可以在PSMA上进行交易.第一个步骤-第一个步骤

更多相关视频

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...